• Country
    Clear
  • Type
  • Compatibility Level
  • Thematic
  • Jurisdiction
1,673 Data sources

  • NL
  • CZ

  • The Mitochondrial Disease Sequence Data Resource (MSeqDR) is a centralized genome and phenome bioinformatics resource built by the mitochondrial disease community to facilitate clinical diagnosis and research investigations of individual patient phenotypes, genomes, genes, and variants. It integrates community knowledge from expert‐curated databases with genomic and phenotype data shared by clinicians and researchers.

    more_vert
  • more_vert
  • more_vert
  • DANS Data Station Physical and Technical Sciences

    more_vert
  • more_vert
  • more_vert
  • GlobalFungi is a collection and validation of data published on the composition of fungal communities in terrestrial environments including soil and plant-associated habitats. Users can search for individual sequences, fungal species hypotheses, species or genera, to get a visual representation of their distribution in the environment and to access and download sequence data and metadata. In addition, the user interface also allows authors to submit data from studies not yet covered and in this way to help to build the resource for the community of researchers in systematics, biogeography, and ecology of fungi.

    more_vert
  • ChannelsDB is a comprehensive and regularly updated resource of channels, pores and tunnels found in biomacromolecules deposited in the Protein Data Bank. The database contains information about channel positions, geometry and physicochemical properties.

    more_vert
  • Nearly 60% of patients undergoing cancer treatment are estimated to have had at least one potential drug-drug interaction; for patients receiving oral anticancer therapy, up to 50% have been reported to experience a potential drug-drug interaction, with 16% experiencing a major event. Drug-drug interactions are therefore a significant issue for cancer patients and the health care professionals who treat them. Combining the internationally recognised drug-drug interactions expertise of the University of Liverpool (UK) with the clinical pharmacology in oncology and haemotology expertise of Radboud University, Nijmegen (the Netherlands), this site was established in 2017 in response to the need for improved management of DDIs with anti-cancer agents.

    more_vert
  • more_vert
  • chevron_left
  • 1
  • 2
  • 3
  • 4
  • 5
  • chevron_right
1,673 Data sources
  • The Mitochondrial Disease Sequence Data Resource (MSeqDR) is a centralized genome and phenome bioinformatics resource built by the mitochondrial disease community to facilitate clinical diagnosis and research investigations of individual patient phenotypes, genomes, genes, and variants. It integrates community knowledge from expert‐curated databases with genomic and phenotype data shared by clinicians and researchers.

    more_vert
  • more_vert
  • more_vert
  • DANS Data Station Physical and Technical Sciences

    more_vert
  • more_vert
  • more_vert
  • GlobalFungi is a collection and validation of data published on the composition of fungal communities in terrestrial environments including soil and plant-associated habitats. Users can search for individual sequences, fungal species hypotheses, species or genera, to get a visual representation of their distribution in the environment and to access and download sequence data and metadata. In addition, the user interface also allows authors to submit data from studies not yet covered and in this way to help to build the resource for the community of researchers in systematics, biogeography, and ecology of fungi.

    more_vert
  • ChannelsDB is a comprehensive and regularly updated resource of channels, pores and tunnels found in biomacromolecules deposited in the Protein Data Bank. The database contains information about channel positions, geometry and physicochemical properties.

    more_vert
  • Nearly 60% of patients undergoing cancer treatment are estimated to have had at least one potential drug-drug interaction; for patients receiving oral anticancer therapy, up to 50% have been reported to experience a potential drug-drug interaction, with 16% experiencing a major event. Drug-drug interactions are therefore a significant issue for cancer patients and the health care professionals who treat them. Combining the internationally recognised drug-drug interactions expertise of the University of Liverpool (UK) with the clinical pharmacology in oncology and haemotology expertise of Radboud University, Nijmegen (the Netherlands), this site was established in 2017 in response to the need for improved management of DDIs with anti-cancer agents.

    more_vert
  • more_vert
  • chevron_left
  • 1
  • 2
  • 3
  • 4
  • 5
  • chevron_right